Volume Alert - MRK 59.72 Merck & Company $MRK Hit a high today of 59.75 Closing the day 10:29 at 59.72 +0.26 +0.44% With a day low of 59.15 and a total volume of 1,484,683.
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - 42 mins ago
Executive Summary
MRK: 59.86 (+0.40), GSK: 46.13 (+0.25), NVS: 95.62 (+1.24)
Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST
NVO: 44.18 (+0.58), PFE: 30.65 (+0.33), MRK: 59.86 (+0.40), LLY: 67.98 (+0.69), SNY: 48.36 (+0.82), MNKD: 6.60 (+0.34)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 212.77 (+3.57), MRK: 59.86 (+0.40), ABBV: 65.95 (+0.91), BMY: 58.60 (+0.17)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.77 (+3.57), ACT: 263.82 (+15.88), VRX: 141.41 (+4.68), MRK: 59.86 (+0.40), VRX.TO: 159.95 (+5.55)
Merck PD-1 inhibitor extends PFS in melanoma
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:59PM CST
MRK: 59.86 (+0.40)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.98 (+0.68), GILD: 102.44 (+2.00), GERN: 3.10 (+0.12), MRK: 59.86 (+0.40), AZN: 73.74 (+1.24), PFE: 30.65 (+0.33), INCY: 69.62 (-0.08), BMY: 58.61 (+0.18), CTIC: 2.29 (+0.05), NVS: 95.63 (+1.25)
Merck (MRK) Breaks Through Resistance at $59.49
Comtex SmarTrend(R) - Mon Nov 17, 2:47PM CST
Merck (NYSE:MRK) has opened bullishly above the pivot of $59.13 today and has reached the first level of resistance at $59.49. Should the shares continue to rise, the resistance pivots of $59.91 and $60.69 will be of interest.
MRK: 59.86 (+0.40)
Will Merck (MRK) Stock Be Helped Today by Zetia Study?
at The Street - Mon Nov 17, 1:53PM CST
Shares of Merck (MRK) are up after the embattled drug Zetia proved effective at reducing the risk of heart attacks, strokes and other heart problems in a large, long-awaited trial.
MRK: 59.86 (+0.40)
Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations
PR Newswire - Mon Nov 17, 1:32PM CST
Nopras Technologies (www.nopras-tech.com) has announced the appointment of Stewart B. Rosenberg to the position of Director, Business Development - East Coast Operations. Mr. Rosenberg joins Nopras from Bio-Investigations Ltd., a specialized global venture capital and new business development consultancy he founded 27 years ago, focused in the fields of human, veterinary, and agricultural health care. With undergraduate and graduate degrees in biology, biochemistry, and business from The University of Connecticut, the University of Pennsylvania, and Wharton, Mr. Rosenberg's corporate career began at Centocor (Malvern, PA), now a division of Johnson & Johnson, where he managed the In Vivo Business Unit, and at EMDS (Gibbstown, NJ), then the U.S. subsidiary of E. Merck (Darmstadt, Germany), where he managed Technology / New Ventures. Rosenberg will be geographically located for Nopras on the Eastern U.S. Coast, to particularly address the needs of biotechnology and biopharmaceutical companies heavily focused along the Boston-Washington Corridor. The position carries global responsibility.
JNJ: 108.98 (+0.68), MRK: 59.86 (+0.40)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.65 (+0.33), MRK: 59.86 (+0.40), AMGN: 161.31 (+2.17), REGN: 410.51 (+10.86)
Vytorin successful in lowering cardiovascular events versus statin alone
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 12:02PM CST
MRK: 59.86 (+0.40)
Study lifts cloud over heart drugs Zetia, Vytorin
By MARILYNN MARCHIONE - AP - Mon Nov 17, 11:01AM CST
CHICAGO (AP) — A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.
MRK: 59.86 (+0.40)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 209.08 (+3.09), PFE: 30.65 (+0.33), MRK: 59.86 (+0.40), AZN: 73.74 (+1.24), ABBV: 65.95 (+0.91)
VYTORIN(R) (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Business Wire - Mon Nov 17, 10:45AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN(R) (ezetimibe/simvastatin) - which combines simvastatin with the non-statin ZETIA(R) (ezetimibe) -- experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.86 (+0.40)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 21.20 (+0.05), KOS: 9.42 (-0.02), KIN: 8.92 (+0.17), VSAT: 66.25 (+0.39), RFMD: 14.03 (+0.68), EBAY: 55.28 (+0.45), TQNT: 23.41 (+1.21), IDIX: 24.50 (+0.05), SEMI: 16.66 (-0.09), VRTV: 48.16 (+0.57), THRX: 13.35 (+0.05), TBPH: 16.55 (-0.77), IMOS: 21.57 (+0.44), ELOS: 9.96 (-0.04), MU: 32.78 (+0.49), AR: 52.31 (+0.04), NCQ: 0.71 (unch), PBF: 27.81 (+0.27), LNG: 71.67 (+0.22), ATRA: 26.20 (-0.47), KERX: 15.87 (+0.69), NG: 3.03 (+0.12), AOI: 1.86 (unch), FWP: 21.40 (-0.32), BYD: 11.64 (-0.03), ALDW: 17.45 (+0.07), SUNE: 20.69 (+4.08), MRK: 59.86 (+0.40), AVEO: 0.98 (-0.01), AIG: 54.04 (+0.02)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - Mon Nov 17, 9:04AM CST
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.65 (+0.33), MRK: 59.86 (+0.40), AZN: 73.74 (+1.24)
Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
Business Wire - Mon Nov 17, 7:30AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today.
MRK: 59.86 (+0.40)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 141.41 (+4.68), ACT: 263.84 (+15.90), F: 15.49 (-0.05), FB: 74.17 (-0.07), PFE: 30.65 (+0.33), AGN: 212.77 (+3.57), YHOO: 52.12 (-0.25), PBR: 9.15 (-0.18), DFS: 65.21 (-0.03), DTSI: 33.44 (+1.16), SPY: 205.33 (+0.96), LNKD: 223.34 (+0.06), QQQ: 103.56 (+0.65), AME: 50.92 (-0.14), MRK: 59.86 (+0.40), AOL: 46.14 (-0.57), AZN: 73.74 (+1.24), GM: 32.30 (-0.01), CVEO: 10.54 (+0.07), DD: 71.12 (+0.65)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 73.74 (+1.24), MRK: 59.86 (+0.40), PFE: 30.65 (+0.33)
MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
Business Wire - Sun Nov 16, 3:25AM CST
--Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress
MRK: 59.86 (+0.40)
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - 42 mins ago
Executive Summary
MRK: 59.86 (+0.40), GSK: 46.13 (+0.25), NVS: 95.62 (+1.24)
Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST
NVO: 44.18 (+0.58), PFE: 30.65 (+0.33), MRK: 59.86 (+0.40), LLY: 67.98 (+0.69), SNY: 48.36 (+0.82), MNKD: 6.60 (+0.34)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 212.77 (+3.57), MRK: 59.86 (+0.40), ABBV: 65.95 (+0.91), BMY: 58.60 (+0.17)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.77 (+3.57), ACT: 263.82 (+15.88), VRX: 141.41 (+4.68), MRK: 59.86 (+0.40), VRX.TO: 159.95 (+5.55)
Merck PD-1 inhibitor extends PFS in melanoma
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:59PM CST
MRK: 59.86 (+0.40)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.98 (+0.68), GILD: 102.44 (+2.00), GERN: 3.10 (+0.12), MRK: 59.86 (+0.40), AZN: 73.74 (+1.24), PFE: 30.65 (+0.33), INCY: 69.62 (-0.08), BMY: 58.61 (+0.18), CTIC: 2.29 (+0.05), NVS: 95.63 (+1.25)
Merck (MRK) Breaks Through Resistance at $59.49
Comtex SmarTrend(R) - Mon Nov 17, 2:47PM CST
Merck (NYSE:MRK) has opened bullishly above the pivot of $59.13 today and has reached the first level of resistance at $59.49. Should the shares continue to rise, the resistance pivots of $59.91 and $60.69 will be of interest.
MRK: 59.86 (+0.40)
Will Merck (MRK) Stock Be Helped Today by Zetia Study?
at The Street - Mon Nov 17, 1:53PM CST
Shares of Merck (MRK) are up after the embattled drug Zetia proved effective at reducing the risk of heart attacks, strokes and other heart problems in a large, long-awaited trial.
MRK: 59.86 (+0.40)
Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations
PR Newswire - Mon Nov 17, 1:32PM CST
Nopras Technologies (www.nopras-tech.com) has announced the appointment of Stewart B. Rosenberg to the position of Director, Business Development - East Coast Operations. Mr. Rosenberg joins Nopras from Bio-Investigations Ltd., a specialized global venture capital and new business development consultancy he founded 27 years ago, focused in the fields of human, veterinary, and agricultural health care. With undergraduate and graduate degrees in biology, biochemistry, and business from The University of Connecticut, the University of Pennsylvania, and Wharton, Mr. Rosenberg's corporate career began at Centocor (Malvern, PA), now a division of Johnson & Johnson, where he managed the In Vivo Business Unit, and at EMDS (Gibbstown, NJ), then the U.S. subsidiary of E. Merck (Darmstadt, Germany), where he managed Technology / New Ventures. Rosenberg will be geographically located for Nopras on the Eastern U.S. Coast, to particularly address the needs of biotechnology and biopharmaceutical companies heavily focused along the Boston-Washington Corridor. The position carries global responsibility.
JNJ: 108.98 (+0.68), MRK: 59.86 (+0.40)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.65 (+0.33), MRK: 59.86 (+0.40), AMGN: 161.31 (+2.17), REGN: 410.51 (+10.86)
Vytorin successful in lowering cardiovascular events versus statin alone
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 12:02PM CST
MRK: 59.86 (+0.40)
Study lifts cloud over heart drugs Zetia, Vytorin
By MARILYNN MARCHIONE - AP - Mon Nov 17, 11:01AM CST
CHICAGO (AP) — A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.
MRK: 59.86 (+0.40)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 209.08 (+3.09), PFE: 30.65 (+0.33), MRK: 59.86 (+0.40), AZN: 73.74 (+1.24), ABBV: 65.95 (+0.91)
VYTORIN(R) (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Business Wire - Mon Nov 17, 10:45AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN(R) (ezetimibe/simvastatin) - which combines simvastatin with the non-statin ZETIA(R) (ezetimibe) -- experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.86 (+0.40)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 21.20 (+0.05), KOS: 9.42 (-0.02), KIN: 8.92 (+0.17), VSAT: 66.25 (+0.39), RFMD: 14.03 (+0.68), EBAY: 55.28 (+0.45), TQNT: 23.41 (+1.21), IDIX: 24.50 (+0.05), SEMI: 16.66 (-0.09), VRTV: 48.16 (+0.57), THRX: 13.35 (+0.05), TBPH: 16.55 (-0.77), IMOS: 21.57 (+0.44), ELOS: 9.96 (-0.04), MU: 32.78 (+0.49), AR: 52.31 (+0.04), NCQ: 0.71 (unch), PBF: 27.81 (+0.27), LNG: 71.67 (+0.22), ATRA: 26.20 (-0.47), KERX: 15.87 (+0.69), NG: 3.03 (+0.12), AOI: 1.86 (unch), FWP: 21.40 (-0.32), BYD: 11.64 (-0.03), ALDW: 17.45 (+0.07), SUNE: 20.69 (+4.08), MRK: 59.86 (+0.40), AVEO: 0.98 (-0.01), AIG: 54.04 (+0.02)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - Mon Nov 17, 9:04AM CST
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.65 (+0.33), MRK: 59.86 (+0.40), AZN: 73.74 (+1.24)
Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
Business Wire - Mon Nov 17, 7:30AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today.
MRK: 59.86 (+0.40)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 141.41 (+4.68), ACT: 263.84 (+15.90), F: 15.49 (-0.05), FB: 74.17 (-0.07), PFE: 30.65 (+0.33), AGN: 212.77 (+3.57), YHOO: 52.12 (-0.25), PBR: 9.15 (-0.18), DFS: 65.21 (-0.03), DTSI: 33.44 (+1.16), SPY: 205.33 (+0.96), LNKD: 223.34 (+0.06), QQQ: 103.56 (+0.65), AME: 50.92 (-0.14), MRK: 59.86 (+0.40), AOL: 46.14 (-0.57), AZN: 73.74 (+1.24), GM: 32.30 (-0.01), CVEO: 10.54 (+0.07), DD: 71.12 (+0.65)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 73.74 (+1.24), MRK: 59.86 (+0.40), PFE: 30.65 (+0.33)
MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
Business Wire - Sun Nov 16, 3:25AM CST
--Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress
MRK: 59.86 (+0.40)
